Bristol Myers Squibb’s Camzyos™ (mavacamten) has been approved to improve functional capacity and symptoms as a treatment for symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) in adults. Camzyos is the first drug in its class to receive FDA approval for this indication.

• Obstructive HCM occurs when a wall of muscle in the heart becomes thicker than normal and interferes with blood flow. Usually, the condition is caused by genetic mutations.
• Due to a risk of heart failure, Camzyos dosing must be individualized based on the patient’s clinical status and echocardiographic assessments of treatment response. The medication is taken once daily by mouth.
• Camzyos has launched at an annual wholesale acquisition cost (WAC) of $89,500.